| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2082114 | Drug Discovery Today: Disease Models | 2012 | 6 Pages |
Abstract
Antagonists targeting the G-protein coupled receptors for endothelin-1 (ET-1) or bradykinin (BK) are clinically indicated to alleviate morbidity related to primary pulmonary hypertension and digital ulcers associated with Raynaud's syndrome or non-allergic angioedema, respectively.Despite the extensively documented functional cross talks between ET-1 and BK in cardiovascular diseases, none of the currently used antagonists for the two peptides target cardiovascular related pain perception as a primary endpoint.This review highlights the role of both peptides as biomarkers and as modulators of nociceptive responses in specific cardiac and vascular diseases.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Martin Houde, Walid Semaan, Giles Rae, Pedro D’Orléans-Juste,